Can Axsome Therapeutics (AXSM) Keep Justifying Its Price On Sales?

Axsome Therapeutics has turned into a very different stock over the past few years, yet the live question for investors is whether a share price at this level is adequately backed by the company’s current sales base. With the spotlight back on its psychiatry and neurology portfolio after fresh data at Psych Congress 2026, the issue is how much revenue traction the market is assuming.

• Over the past 5 years the stock has delivered a very large cumulative gain, which puts a lot of weight on how its sales stack up against the current share price.
• New findings on agitation in Alzheimer’s disease and on dextromethorphan bupropion in major depressive disorder may support expectations for future prescription volumes, which feeds directly into how investors frame Axsome Therapeutics’ potential revenue path.
• There is a second opinion on Axsome Therapeutics worth weighing. See what analysts think Axsome Therapeutics's shares could be worth.

The stock's next move may depend on whether Axsome Therapeutics’ present market value is reasonably grounded in the sales the business is generating today.

If you want to stress test the same question hanging over Axsome Therapeutics, compare it with other stocks screened for 32 high quality undervalued stocks

Is Axsome Therapeutics Still Cheap on Sales?

P/S is usually a better yardstick for a business like Axsome Therapeutics that is still loss making and being valued on its revenue base. On that measure, the stock trades on a P/S of 12.6x, compared with a Pharmaceuticals industry average of 4.9x and a peer group around 10.2x. That leaves Axsome priced at a premium to both the wider sector and to closer comparables.

Because the fair multiple for Axsome Therapeutics, which blends factors such as its growth profile, margins, size and risk, sits above the industry and peer yardsticks, the current 12.6x is below what this tailored model would imply. The new Psych Congress 2026 data on Alzheimer’s agitation and dextromethorphan bupropion means the stock is being discussed heavily, yet the P/S still screens at a discount to that fair benchmark. This is what the detailed valuation output is designed to quantify. Explore the numbers behind Axsome Therapeutics's P/S valuation.

The Axsome Therapeutics Narrative: What Would Justify Today's Price?

Narratives on Simply Wall St pick up where Axsome Therapeutics' valuation puzzle leaves off and outline which future paths for growth, margins and earnings would need to hold for the shares to be worth clearly more or clearly less than today’s price, all housed on the Community page. Each version treats Axsome Therapeutics' fair value as a thesis about the business that you can track over time, rather than a one off snapshot.

One of the top community narratives on Axsome Therapeutics: 34% undervalued

"Diverse CNS product portfolio and late-stage pipeline position company to capitalize on global demand trends while reducing dependence on single products..."

Discover why this Narrative puts Axsome Therapeutics at 34% undervalued.

One more Axsome Therapeutics check that belongs beside the price tag

The numbers tell one story, but any investor in Axsome Therapeutics also needs to know who is steering the ship, how they are rewarded, and whether those incentives line up with shareholders. See who runs Axsome Therapeutics and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com